November 2, 2020 Uncategorized

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment... Read more

October 29, 2020 Uncategorized

Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer The Tecentriq combination improved overall survival and progression-free survival compared with sorafenib in people with unresectable HCC Approval by the China National Medical Products Administration brings... Read more

October 22, 2020 Bio/Pharma/CRO M&A, Partnerships

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings Oral,... Read more

October 19, 2020 Acad, Gov/Utilities Bio/Pharma/CRO PAI Top-10

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia

Approval supported by data from phase III confirmatory trials, VIALE-A and VIALE-C VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML compared to azacitidine alone Supplemental New Drug Applications approved under the FDA’s Real-Time Oncology Review pilot programme and Project Orbis initiative              Basel, 19 October 2020 – Roche (SIX: RO,... Read more

October 15, 2020 Uncategorized

First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic

Basel, 15 October 2020 Group sales increase 1%1 at constant exchange rates and decline 5% in Swiss francs as a result of continued appreciation of the Swiss franc against most currencies Impact of COVID-19 pandemic: Following strong sales growth in the first quarter (+7%) and COVID-19 related decline in the second quarter (-4%) sales stabilise... Read more

October 13, 2020 Uncategorized

Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

Basel, 13 October 2020 The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analysers which are widely available around the world, thus helping to increase testing capacity In combination with other COVID-19 diagnostic... Read more

September 19, 2020 Bio/Pharma/CRO Licensing, IP, and Legal Product Launch

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy Final overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours... Read more

September 18, 2020 PR/Corporate

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Recommendation is based on the results of the IMbrave150 study, in which the Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)... Read more

September 18, 2020 PAI Top-10 Product Launch

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test  targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.1 Using the Elecsys Anti-SARS-COV-2 S antibody test, together with the Elecsys... Read more